Tuberous Sclerosis Complex (TSC): Market View, Current and Future Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Assess the Tuberous Sclerosis Complex therapeutics market with marketed products, pipeline drugs, clinical trials, deals, pricing, reimbursement, and competitive insights.
Why Does the Tuberous Sclerosis Complex Therapeutics Market Matter?
Tuberous Sclerosis Complex (TSC) is a multidisciplinary disease requiring symptom-driven management across seizures, TSC-associated tumors, and organ-specific manifestations affecting the brain, kidneys, lungs, skin, and heart.
In 2025, there were 198,627 diagnosed prevalent cases of TSC-associated epilepsy across the 16 countries covered in GlobalData’s epidemiology forecast. Treatment includes anti-seizure medications, dietary and surgical options for refractory epilepsy, surveillance, and supportive interventions. Marketed mTOR therapies such as everolimus and topical sirolimus are important components of treatment for specific TSC manifestations, while therapies including vigabatrin and cannabidiol are used for TSC-associated seizures in relevant patient populations.
The TSC pipeline contains 18 molecules, including one asset at pre-registration, one in Phase III, and three in Phase II development. Over the past decade, 85 clinical trials have been conducted in TSC, providing a substantial body of clinical development activity to assess alongside the marketed and emerging treatment landscape.
You can use this report to:
- Assess the current and future TSC therapeutics landscape
- Analyze marketed TSC products and their performance
- Track the TSC pipeline by development stage
- Identify companies with robust TSC pipelines
- Assess clinical trial activity and development trends
- Evaluate pricing and reimbursement considerations
- Analyze recent deals, partnerships, and acquisitions
- Identify emerging competitors and treatment opportunities
- Assess mechanisms of action, molecule types, and routes of administration
- Support licensing, investment, commercial, and competitive strategies
Key Insights in the Tuberous Sclerosis Complex Therapeutics Market
The report highlights key developments across the TSC treatment and competitive landscape:
- 198,627 diagnosed prevalent cases of TSC-associated epilepsy were recorded across the 16 countries covered by GlobalData’s epidemiology forecast in 2025.
- The latest updated international consensus guidance for TSC diagnosis and treatment was established in 2021 by the International TSC Consensus Group.
- TSC treatment is multidisciplinary and symptom-driven, covering seizure control, TSC-associated tumors, and organ-specific care.
- Marketed mTOR therapies include everolimus for subependymal giant cell astrocytoma (SEGA) and renal angiomyolipoma, and topical sirolimus for facial angiofibromas in some markets.
- Vigabatrin is commonly used as a first-line treatment for TSC-associated infantile spasms, with vision-toxicity monitoring.
- Cannabidiol is approved for TSC-associated seizures in certain age groups.
- The TSC pipeline contains 18 molecules, including one pre-registration asset, one Phase III asset, and three Phase II assets.
- 85 TSC clinical trials have been conducted over the past decade.
- The highest number of trials initiated in this period occurred in 2022, with 14 trials, followed by 2021 with 13.
- Everolimus was the most frequently studied drug in 2022, featuring in six of the 14 trials initiated that year.
- Licensing agreements represented the largest share of TSC-related deals in South America, followed by the Middle East and Africa, Asia-Pacific, Europe, and North America.
- Partnerships were most prevalent in Europe, followed by Asia-Pacific, South America, North America, and the Middle East and Africa.
- The report assesses mergers, acquisitions, and strategic alliances across regions.
Scope
What Will You Learn from This Tuberous Sclerosis Complex Competitive Analysis Report?
This report provides insight into:
- The TSC disease landscape
- TSC epidemiology
- TSC treatment approaches
- Marketed TSC products
- Product sales forecasts
- Mechanisms of action
- Molecule types
- Pricing and reimbursement
- Annual therapy costs
- Time to pricing
- Time to reimbursement
- The TSC drug pipeline
- Pipeline development stages
- Late-to-mid-stage pipeline drugs
- Routes of administration
- Phase transition success rates
- Likelihood of approval
- Clinical trial activity
- Clinical trial sponsors
- Trial phases and statuses
- Trial geographies and endpoints
- Enrollment and site analytics
- Clinical trial feasibility
- TSC-related deals
- Licensing agreements
- Partnerships
- Mergers and acquisitions
- Strategic alliances
- Key market players
- Future market catalysts
Who Should Buy This Tuberous Sclerosis Complex Competitive Analysis Report?
This report may be valuable for:
- Pharmaceutical companies
- Biotechnology companies
- Drug developers
- Rare disease therapeutics companies
- Clinical development teams
- Commercial strategy teams
- Business development teams
- Licensing teams
- Market access teams
- Pricing and reimbursement teams
- Sales and marketing teams
- Competitive intelligence teams
- Corporate strategy teams
- Healthcare investors
- Investment analysts
How Companies Use This Tuberous Sclerosis Complex Competitive Analysis
Companies can use this report to:
- Benchmark marketed TSC products and competitors
- Identify companies with robust TSC pipelines
- Assess pipeline assets by development stage
- Analyze mechanisms of action and molecule types
- Evaluate late-to-mid-stage development opportunities
- Assess clinical trial activity and sponsor participation
- Analyze trial enrollment, sites, geographies, and endpoints
- Assess pricing and reimbursement considerations
- Understand annual therapy costs
- Monitor licensing agreements and strategic partnerships
- Identify merger and acquisition activity
- Identify emerging players with potentially strong product portfolios
- Develop in-licensing and out-licensing strategies
- Inform sales and marketing strategies
- Identify opportunities for consolidation, investment, and strategic partnerships
- Support competitive response strategies
Reasons to Buy
Benchmark the Global Tuberous Sclerosis Complex Landscape
The report enables stakeholders to benchmark the TSC therapeutics landscape across:
- Marketed products
- Pipeline molecules
- Development stages
- Mechanisms of action
- Molecule types
- Routes of administration
- Product sales forecasts
- Clinical trials
- Trial sponsors
- Trial geographies
- Trial endpoints
- Deals and strategic alliances
- Key market players
Regional deal activity can also be assessed across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa, providing insight into different approaches to licensing, partnerships, and other strategic transactions.
Built on GlobalData Pharma Intelligence
GlobalData’s Tuberous Sclerosis Complex: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a data-driven competitive assessment of the TSC therapeutics marketplace.
The analysis brings together disease, epidemiology, treatment, marketed products, pipeline, clinical trials, pricing and reimbursement, deals, and commercial intelligence to provide a comprehensive view of the competitive landscape.
Act Now to Identify Opportunities in Tuberous Sclerosis Complex Therapeutics
Use this report to assess the evolving TSC therapeutics landscape, benchmark marketed and pipeline products, monitor clinical development, and identify companies and assets shaping the future market.
Analyze pipeline opportunities, competitive performance, clinical trials, pricing and reimbursement, and deal activity to support licensing, investment, commercial strategy, and business-development decisions.
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Tuberous Sclerosis Complex (TSC): Market View, Current and Future Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
